{"url_path":"/sec/capr/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-060382-index.html","accession_number":"0001104659-26-060382","cik":"0001133869","ticker":"CAPR","issuer_name":"CAPRICOR THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-060382-index.html","primary_entity_key":"0001133869","primary_entity_name":"CAPRICOR THERAPEUTICS, INC."},"word_count":180,"has_tables":true,"body_markdown":"**Item 5.  Other Information.**\n\n*Rule 10b5-1 Trading Arrangements*\n\nDuring the three months ended March 31, 2026, none of the directors or executive officers of the Company adopted or terminated any contracts, instructions, or written plans for the purchase or sale of the Company’s securities that were intended to meet the affirmative defense conditions of Rule 10b5-1(c) (“Rule 10b5-1 Plan”) or any other “non-Rule 10b5-1 trading arrangement”.\n\nWe inadvertently omitted the disclosure of a Rule 10b5-1 Plan adopted by Karimah Es Sabar, one of our directors, on December 27, 2025, in Item 9B of Part II of our Annual Report on Form 10-K for the year ended December 31, 2025.  The details of this plan are set forth below.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**Name**\n\n  ​ ​ ​\n\n**Title**\n\n  ​ ​ ​\n\n**Action**\n\n  ​ ​ ​\n\n**Date Adopted or********Terminated**\n\n  ​ ​ ​\n\n**Plan End Date**\n\n  ​ ​ ​\n\n**Aggregate Shares**\n\nKarimah Es Sabar\n\n​\n\nBoard of Director\n\n​\n\nAdoption of Rule 10b5-1 trading plan\n\n​\n\n12/27/2025\n\n​\n\n06/01/2026\n\n​\n\nUp to 122,529 shares\n\n​"}